It has been reported that CXCL10 is able to recruit additional CD8+ T cells from circulation to the tumor microenvironment via a chemokine gradient, resulting in CXCL10 being a good prognostic marker in patients with metastatic, cutaneous, or uveal melanoma treated with immune checkpoint blockade or tebentafusp [7,13]. Here, CXCL10 is linked to uveal melanoma.